Pharmaceutical application of betaine for treatment of pulmonary arterial hypertension

A technology of pulmonary arterial hypertension and betaine, which is applied in the field of betaine as a drug for the treatment of pulmonary arterial hypertension, to achieve the effects of reducing right ventricular systolic blood pressure, reducing right ventricular hypertrophy index, and reducing remodeling of small and medium pulmonary arteries

Inactive Publication Date: 2017-09-15
NINGXIA MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies at home and abroad have shown that betaine can promote fat metabolism and reduce homocysteine ​​in the body; it has pharmacological effects such as anti-fatty liver, kidney protection, blood pressure lowering, anti-tumor, and stress relief, but there is little information about its inhibitory effect on pulmonary hypertension. see literature report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of betaine for treatment of pulmonary arterial hypertension
  • Pharmaceutical application of betaine for treatment of pulmonary arterial hypertension
  • Pharmaceutical application of betaine for treatment of pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The use of betaine as a drug for treating pulmonary hypertension, wherein the single application dose of betaine is 100 mg / kg for rats, and the dosage form of the drug is a solution dosage form.

Embodiment 2

[0037] The use of betaine as a drug for treating pulmonary hypertension, wherein the single application dose of betaine is 200 mg / kg for rats, and the dosage form of the drug is a powder injection dosage form.

Embodiment 3

[0039] The use of betaine as a drug for treating pulmonary hypertension, wherein the single application dose of betaine is 400 mg / kg for rats, and the dosage form of the drug is powder injection dosage form.

[0040] The following animal experiment has further illustrated the effect of above-mentioned embodiment 1 to 3:

[0041] 1. Experimental materials

[0042] 1.1 Animal handling

[0043] Adult male SD rats, 260-300g, were purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: NCXK (Ning) 2016-0005. Feeding conditions include standard feed, tap water, room temperature maintained at (24±2)°C, humidity 50-60%, and daily light and dark times of 12 hours each. Before the experiment, the animals were placed in the experimental environment for 3 days to adapt.

[0044] 1.2 Experimental drugs and instruments

[0045] Betaine (US Sigma Company), prepared with normal saline, the concentrations were 100mg / mL, 200mg / mL, 400mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of betaine in preparation of medicines for treatment of pulmonary arterial hypertension. A test result proves that in a safety dose range, the betaine, in the dosage of 400 mg/kg, can significantly improve average pulmonary arterial pressure and right ventricular systolic pressure, reduce remodeling of right ventricular and arteriole in lung and solve inflammatory response in lung tissue of adult rats. The invention proves that the betaine has treatment effects on the pulmonary arterial hypertension.

Description

technical field [0001] The invention relates to the application of betaine, in particular to the application of betaine as a medicine for treating pulmonary hypertension. Background technique [0002] Pulmonary arterial hypertension (PAH) is a group of pulmonary vascular remodeling diseases characterized by continuous increase in pulmonary vascular resistance caused by heterogeneous diseases and different pathogenesis, leading to right ventricular failure and death. rate, high disability rate, and high mortality rate, it is considered a "pseudo-malignant tumor". Vascular smooth muscle cell proliferation, pulmonary vascular remodeling, and pulmonary artery occlusion caused by pulmonary vascular endothelial injury caused by inflammation are considered to be the main features of the pathogenesis and pathological changes of pulmonary arterial hypertension. Due to the increase of pulmonary vascular resistance and the increase of right ventricular afterload, right ventricular rem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/205A61P9/12
CPCA61K31/205
Inventor 周茹杨佳美余建强刘宁谭焕然
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap